6 results on '"Badoer C"'
Search Results
2. Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples
- Author
-
Céline Garrec, Jurgen Del Favero, Capucine Delnatte, Dirk Goossens, Paola Concolino, Ettore Capoluongo, Cindy Badoer, Stéphane Bézieau, Gillian Ellison, Mélina Dzial, John Mills, Hakim El Housni, Sarah Berwouts, Virginie Guibert-Le Guevellou, Badoer, C, Garrec, C, Goossens, D, Ellison, G, Mills, J, Dzial, M, El Housni, H, Berwouts, S, Concolino, P, Guibert-Le Guevellou, V, Delnatte, C, Del Favero, J, Capoluongo, E, and Bezieau, S
- Subjects
0301 basic medicine ,Oncology ,Heredity ,endocrine system diseases ,DNA Mutational Analysis ,fresh frozen tumor ,chemistry.chemical_compound ,Olaparib ,0302 clinical medicine ,Settore BIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA ,Gene Frequency ,Ovarian carcinoma ,Freezing ,skin and connective tissue diseases ,Genetics ,Ovarian Neoplasms ,next generation sequencing ,BRCA1 Protein ,High-Throughput Nucleotide Sequencing ,Europe ,fresh frozen tumors ,030220 oncology & carcinogenesis ,Female ,BRCA1-BRCA2 ,Research Paper ,medicine.medical_specialty ,Fresh frozen tumors ,Breast Neoplasms ,olaparib ,DNA sequencing ,Specimen Handling ,03 medical and health sciences ,Germline mutation ,Predictive Value of Tests ,Next generation sequencing ,Molecular genetics ,Internal medicine ,Multiplex polymerase chain reaction ,medicine ,Biomarkers, Tumor ,Humans ,Genetic Predisposition to Disease ,Allele frequency ,BRCA2 Protein ,business.industry ,Reproducibility of Results ,medicine.disease ,ovarian carcinoma ,030104 developmental biology ,chemistry ,Mutation ,Reagent Kits, Diagnostic ,business ,Ovarian cancer ,Multiplex Polymerase Chain Reaction ,Psychiatrie - Abstract
Next-generation sequencing (NGS) has enabled new approaches for detection of mutations in the BRCA1 and BRCA2 genes responsible for hereditary breast and ovarian cancer (HBOC). The search for germline mutations in the BRCA1 and BRCA2 genes is of importance with respect to oncogenetic and surgical (bilateral mastectomy, ovariectomy) counselling. Testing tumor material for BRCA mutations is of increasing importance for therapeutic decision making as the poly ADP ribose polymerase (PARP) inhibitor, olaparib, is now available to treat patients with specific forms of ovarian cancer and BRCA mutations. Molecular genetics laboratories should develop reliable and sensitive techniques for the complete analysis of the BRCA1 and BRCA2 genes. This is a challenge due to the size of the coding sequence of the BRCA1/2 genes, the absence of hot spot mutations, and particularly by the lower DNA quality obtained from Formalin-Fixed Paraffin-Embedded (FFPE) tissue. As a result, a number of analyses are uninterpretable and do not always provide a result to the clinician, limiting the optimal therapeutic management of patients. The availability of Fresh Frozen Tissue (FFT) for some laboratories and the excellent quality of the DNA extracted from it offers an alternative. For this reason, we evaluated Multiplicom's BRCA MASTR Dx assay on a set of 97 FFT derived DNA samples, in combination with the MID for Illumina MiSeq for BRCA1 and BRCA2 mutation detection. We obtained interpretable NGS results for all tested samples and showed > 99,7% sensitivity, specificity and accuracy., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2016
3. POT1 tumour predisposition: a broader spectrum of associated malignancies and proposal for additional screening program.
- Author
-
Baptista Freitas M, Desmyter L, Badoer C, Smits G, Vandernoot I, and T Kint de Roodenbeke D
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Genetic Testing methods, Aged, Genetic Predisposition to Disease, Telomere-Binding Proteins genetics, Shelterin Complex, Pedigree
- Abstract
Protection of Telomeres Protein 1 (POT1) protein is an essential subunit of the shelterin telomere binding complex, regulating telomere length. Some POT1 gene pathogenic variants (PV) lead to telomere elongation, genomic instability and higher risk of cancer. POT1 tumour predisposition syndrome (POT1-TPD) has autosomal dominant inheritance and unknown penetrance. It is associated with increased risk of cutaneous melanoma, chronic lymphocytic leukaemia, angiosarcoma and gliomas. In this work, we aim to describe a broader cancer phenotype related to POT1-TPD, in three families (two with a four generation pedigree, one with a five generation pedigree). The three index cases were referred to our oncogenetic centre for genetic counselling due to their personal history of cancer. Two underwent clinical exome sequencing of 4,867 genes associated with Mendelian genetic diseases, and another underwent gene panel sequencing including POT1, which identified three different POT1 PV: NC_000007.14(NM_015450.2):c.349C>T; NC_000007.14(NM_015450.2):c.233T>C and NC_000007.14(NM_015450.2):c.818G>A; already described in the literature. Referenced relatives, did a target genetic test (according to the POT1 PV identified in the family). In total, 37 individuals were tested (51.4% females), median age of 46 (22-81) years, with POT1 PV detected in 22. POT1-TPD was observed, but also a higher incidence of other cancers (other sarcomas, papillary thyroid cancer, early onset prostate cancer and leukaemia). These findings contribute to an increase in our knowledge about POT1 PV, and it can play a role in the definition of future POT1 PV screening criteria, POT1 carrier surveillance protocols (possibly considering screening for all types of sarcomas) and in genetic counselling., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
4. Phenotypes and genotypes in non-consanguineous and consanguineous primary microcephaly: High incidence of epilepsy.
- Author
-
Duerinckx S, Désir J, Perazzolo C, Badoer C, Jacquemin V, Soblet J, Maystadt I, Tunca Y, Blaumeiser B, Ceulemans B, Courtens W, Debray FG, Destree A, Devriendt K, Jansen A, Keymolen K, Lederer D, Loeys B, Meuwissen M, Moortgat S, Mortier G, Nassogne MC, Sekhara T, Van Coster R, Van Den Ende J, Van der Aa N, Van Esch H, Vanakker O, Verhelst H, Vilain C, Weckhuysen S, Passemard S, Verloes A, Aeby A, Deconinck N, Van Bogaert P, Pirson I, and Abramowicz M
- Subjects
- Cell Cycle Proteins genetics, Child, Epilepsy epidemiology, Epilepsy pathology, Female, Gene Frequency, Genetic Heterogeneity, Humans, Incidence, Male, Microcephaly complications, Microcephaly pathology, Nerve Tissue Proteins genetics, Consanguinity, Epilepsy genetics, Genotype, Microcephaly genetics, Phenotype
- Abstract
Background: Primary microcephaly (PM) is defined as a significant reduction in occipitofrontal circumference (OFC) of prenatal onset. Clinical and genetic heterogeneity of PM represents a diagnostic challenge., Methods: We performed detailed phenotypic and genomic analyses in a large cohort (n = 169) of patients referred for PM and could establish a molecular diagnosis in 38 patients., Results: Pathogenic variants in ASPM and WDR62 were the most frequent causes in non-consanguineous patients in our cohort. In consanguineous patients, microarray and targeted gene panel analyses reached a diagnostic yield of 67%, which contrasts with a much lower rate in non-consanguineous patients (9%). Our series includes 11 novel pathogenic variants and we identify novel candidate genes including IGF2BP3 and DNAH2. We confirm the progression of microcephaly over time in affected children. Epilepsy was an important associated feature in our PM cohort, affecting 34% of patients with a molecular confirmation of the PM diagnosis, with various degrees of severity and seizure types., Conclusion: Our findings will help to prioritize genomic investigations, accelerate molecular diagnoses, and improve the management of PM patients., (© 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
5. Digenic inheritance of human primary microcephaly delineates centrosomal and non-centrosomal pathways.
- Author
-
Duerinckx S, Jacquemin V, Drunat S, Vial Y, Passemard S, Perazzolo C, Massart A, Soblet J, Racapé J, Desmyter L, Badoer C, Papadimitriou S, Le Borgne YA, Lefort A, Libert F, De Maertelaer V, Rooman M, Costagliola S, Verloes A, Lenaerts T, Pirson I, and Abramowicz M
- Subjects
- Animals, Databases, Genetic, Humans, Mutation, Open Reading Frames, Phenotype, Signal Transduction, Exome Sequencing, Zebrafish, Centrosome metabolism, Genetic Association Studies methods, Genetic Predisposition to Disease, Inheritance Patterns, Microcephaly diagnosis, Microcephaly genetics
- Abstract
Primary microcephaly (PM) is characterized by a small head since birth and is vastly heterogeneous both genetically and phenotypically. While most cases are monogenic, genetic interactions between Aspm and Wdr62 have recently been described in a mouse model of PM. Here, we used two complementary, holistic in vivo approaches: high throughput DNA sequencing of multiple PM genes in human patients with PM, and genome-edited zebrafish modeling for the digenic inheritance of PM. Exomes of patients with PM showed a significant burden of variants in 75 PM genes, that persisted after removing monogenic causes of PM (e.g., biallelic pathogenic variants in CEP152). This observation was replicated in an independent cohort of patients with PM, where a PM gene panel showed in addition that the burden was carried by six centrosomal genes. Allelic frequencies were consistent with digenic inheritance. In zebrafish, non-centrosomal gene casc5 -/- produced a severe PM phenotype, that was not modified by centrosomal genes aspm or wdr62 invalidation. A digenic, quadriallelic PM phenotype was produced by aspm and wdr62. Our observations provide strong evidence for digenic inheritance of human PM, involving centrosomal genes. Absence of genetic interaction between casc5 and aspm or wdr62 further delineates centrosomal and non-centrosomal pathways in PM., (© 2019 The Authors. Human Mutation published by Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
6. Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
- Author
-
Badoer C, Garrec C, Goossens D, Ellison G, Mills J, Dzial M, El Housni H, Berwouts S, Concolino P, Guibert-Le Guevellou V, Delnatte C, Del Favero J, Capoluongo E, and Bézieau S
- Subjects
- Breast Neoplasms pathology, Europe, Female, Freezing, Gene Frequency, Genetic Predisposition to Disease, Heredity, High-Throughput Nucleotide Sequencing, Humans, Ovarian Neoplasms pathology, Predictive Value of Tests, Reproducibility of Results, BRCA1 Protein genetics, BRCA2 Protein genetics, Biomarkers, Tumor genetics, Breast Neoplasms genetics, DNA Mutational Analysis methods, Multiplex Polymerase Chain Reaction, Mutation, Ovarian Neoplasms genetics, Reagent Kits, Diagnostic, Specimen Handling methods
- Abstract
Next-generation sequencing (NGS) has enabled new approaches for detection of mutations in the BRCA1 and BRCA2 genes responsible for hereditary breast and ovarian cancer (HBOC). The search for germline mutations in the BRCA1 and BRCA2 genes is of importance with respect to oncogenetic and surgical (bilateral mastectomy, ovariectomy) counselling. Testing tumor material for BRCA mutations is of increasing importance for therapeutic decision making as the poly ADP ribose polymerase (PARP) inhibitor, olaparib, is now available to treat patients with specific forms of ovarian cancer and BRCA mutations. Molecular genetics laboratories should develop reliable and sensitive techniques for the complete analysis of the BRCA1 and BRCA2 genes. This is a challenge due to the size of the coding sequence of the BRCA1/2 genes, the absence of hot spot mutations, and particularly by the lower DNA quality obtained from Formalin-Fixed Paraffin-Embedded (FFPE) tissue. As a result, a number of analyses are uninterpretable and do not always provide a result to the clinician, limiting the optimal therapeutic management of patients. The availability of Fresh Frozen Tissue (FFT) for some laboratories and the excellent quality of the DNA extracted from it offers an alternative. For this reason, we evaluated Multiplicom's BRCA MASTR Dx assay on a set of 97 FFT derived DNA samples, in combination with the MID for Illumina MiSeq for BRCA1 and BRCA2 mutation detection. We obtained interpretable NGS results for all tested samples and showed > 99,7% sensitivity, specificity and accuracy.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.